Nephros Inc NEPH
We take great care to ensure that the data presented and summarized in this overview for NEPHROS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NEPH
View all-
Wexford Capital LP Greenwich, CT3.6MShares$5.76 Million1.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA202KShares$323,1900.0% of portfolio
-
Bard Associates Inc Chicago, IL172KShares$275,7930.11% of portfolio
-
Geode Capital Management, LLC Boston, MA85.2KShares$136,3980.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL57.2KShares$91,5360.0% of portfolio
-
Elkhorn Partners Limited Partnership Omaha, NE36.4KShares$58,3050.04% of portfolio
-
Blair William & CO Chicago, IL36.2KShares$57,9980.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny24.4KShares$39,1100.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il17.2KShares$27,5770.0% of portfolio
-
State Street Corp Boston, MA15.7KShares$25,1160.0% of portfolio
Latest Institutional Activity in NEPH
Top Purchases
Top Sells
About NEPH
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Insider Transactions at NEPH
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 30
2024
|
Arthur H Amron Director |
BUY
Open market or private purchase
|
Direct |
3,000
+2.82%
|
$6,000
$2.24 P/Share
|
May 28
2024
|
Arthur H Amron Director |
BUY
Open market or private purchase
|
Direct |
2,000
+1.95%
|
$4,000
$2.22 P/Share
|
May 16
2024
|
Robert R. Banks Jr. President and CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+41.67%
|
$100,000
$2.24 P/Share
|
Mar 13
2024
|
Wexford Capital LP |
SELL
Other acquisition or disposition
|
Direct |
91,463
-62.0%
|
-
|
Mar 13
2024
|
Arthur H Amron Director |
BUY
Other acquisition or disposition
|
Direct |
91,463
+48.16%
|
-
|
Mar 12
2024
|
Arthur H Amron Director |
BUY
Open market or private purchase
|
Direct |
7,000
+50.0%
|
$14,000
$2.45 P/Share
|
Dec 13
2023
|
Arthur H Amron Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,291
+50.0%
|
-
|
Dec 13
2023
|
Joseph Michael Harris Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,291
+34.43%
|
-
|
Dec 13
2023
|
Alisa Lask Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,291
+16.04%
|
-
|
Dec 13
2023
|
Oliver J. Spandow Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,294
+14.91%
|
-
|
Dec 07
2023
|
Robert R. Banks Jr. President and CEO |
BUY
Open market or private purchase
|
Direct |
18,000
+47.37%
|
$36,000
$2.2 P/Share
|
Aug 15
2023
|
Robert R. Banks Jr. President and CEO |
BUY
Open market or private purchase
|
Direct |
1,901
+48.73%
|
$1,901
$1.69 P/Share
|
Aug 14
2023
|
Robert R. Banks Jr. President and CEO |
BUY
Open market or private purchase
|
Direct |
99
+50.0%
|
$99
$1.5 P/Share
|
Jan 05
2023
|
Joseph Michael Harris Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,402
+50.0%
|
-
|
Jan 05
2023
|
Arthur H Amron Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,613
+50.0%
|
-
|
Jan 05
2023
|
Tom Gwydir Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,613
+38.98%
|
-
|
Jan 05
2023
|
Oliver J. Spandow Director |
BUY
Grant, award, or other acquisition
|
Direct |
42,481
+38.69%
|
-
|
Jan 05
2023
|
Alisa Lask Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,613
+41.24%
|
-
|
Mar 05
2022
|
Andrew Astor President, CEO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
14,815
+13.77%
|
$29,630
$2.7 P/Share
|
Feb 16
2022
|
Wesley S. Lobo Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,389
-15.37%
|
$25,556
$4.8 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 42.2K shares |
---|---|
Other acquisition or disposition | 91.5K shares |
Open market or private purchase | 62K shares |
Other acquisition or disposition | 91.5K shares |
---|